NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.65 +0.18 (+2.13 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$8.65
Today's Range$8.45 - $8.75
52-Week Range$3.90 - $11.90
Volume37,329 shs
Average Volume117,531 shs
Market Capitalization$176.96 million
P/E Ratio-6.18
Dividend YieldN/A
Beta0.55

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Debt-to-Equity Ratio0.03
Current Ratio11.09
Quick Ratio11.09

Price-To-Earnings

Trailing P/E Ratio-6.18
Forward P/E Ratio-5.37
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.07 per share
Price / Book4.18

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-22,340,000.00
Net MarginsN/A
Return on Equity-70.83%
Return on Assets-63.87%

Miscellaneous

Employees12
Outstanding Shares20,110,000

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.06. View Aldeyra Therapeutics' Earnings History.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

6 brokers have issued 12-month target prices for Aldeyra Therapeutics' shares. Their forecasts range from $13.00 to $27.00. On average, they expect Aldeyra Therapeutics' share price to reach $18.50 in the next year. View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (5/21/2018)
  • 2. Canaccord Genuity analysts commented, "We are updating our ALDX model, but our price target remains unchanged at $27. We also maintain current US peak sales estimates." (3/13/2018)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

Has Aldeyra Therapeutics been receiving favorable news coverage?

Headlines about ALDX stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a news sentiment score of 0.15 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (5.13%), Millennium Management LLC (3.83%), Stanley Laman Group Ltd. (0.33%), Dimensional Fund Advisors LP (0.32%), JPMorgan Chase & Co. (0.30%) and Northern Trust Corp (0.24%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. View Insider Buying and Selling for Aldeyra Therapeutics.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Stanley Laman Group Ltd., Millennium Management LLC, Element Capital Management LLC, Northern Trust Corp, Dimensional Fund Advisors LP and JPMorgan Chase & Co.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $8.65.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $176.96 million. The biotechnology company earns $-22,340,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 12 workers across the globe.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]


MarketBeat Community Rating for Aldeyra Therapeutics (ALDX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aldeyra Therapeutics (NASDAQ:ALDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Aldeyra Therapeutics in the last 12 months. Their average twelve-month price target is $18.50, suggesting that the stock has a possible upside of 113.87%. The high price target for ALDX is $27.00 and the low price target for ALDX is $13.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.833.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.50$18.50$18.3333$19.40
Price Target Upside: 113.87% upside164.29% upside152.87% upside205.51% upside

Aldeyra Therapeutics (NASDAQ:ALDX) Consensus Price Target History

Price Target History for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018Cantor FitzgeraldSet Price TargetBuy$23.00HighView Rating Details
4/9/2018CowenReiterated RatingHoldLowView Rating Details
3/13/2018Canaccord GenuityReiterated RatingBuy$27.00LowView Rating Details
3/1/2018Seaport Global SecuritiesReiterated RatingBuyLowView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$18.00LowView Rating Details
5/31/2017Stifel NicolausReiterated RatingBuy$16.00MediumView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Aldeyra Therapeutics (NASDAQ:ALDX) Earnings History and Estimates Chart

Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.39)($0.39)($0.39)
Q4 20181($0.45)($0.45)($0.45)

Aldeyra Therapeutics (NASDAQ ALDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.44)N/AView Earnings Details
5/15/2018Q1 2018($0.37)($0.43)ViewN/AView Earnings Details
3/29/2018Q4 2017($0.32)($0.36)ViewListenView Earnings Details
11/9/2017Q3 2017($0.41)($0.32)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.37)($0.35)ViewListenView Earnings Details
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.30)($0.47)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
6/11/2014Q1 2014($4.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aldeyra Therapeutics (NASDAQ:ALDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aldeyra Therapeutics (NASDAQ ALDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.99%
Institutional Ownership Percentage: 52.03%
Insider Trading History for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ ALDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/19/2017Life Sciences Maste PerceptiveMajor ShareholderBuy200,000$7.25$1,450,000.00View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy296,007$4.60$1,361,632.20View SEC Filing  
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.0017,944View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.503,333View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.5064,408View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aldeyra Therapeutics (NASDAQ ALDX) News Headlines

Source:
DateHeadline
 Brokerages Expect Aldeyra Therapeutics, Inc (ALDX) to Post -$0.39 Earnings Per Share Brokerages Expect Aldeyra Therapeutics, Inc (ALDX) to Post -$0.39 Earnings Per Share
www.americanbankingnews.com - May 22 at 3:10 AM
Seaport Global Securities Comments on Aldeyra Therapeutics, Incs Q3 2018 Earnings (ALDX)Seaport Global Securities Comments on Aldeyra Therapeutics, Inc's Q3 2018 Earnings (ALDX)
www.americanbankingnews.com - May 21 at 1:22 AM
Seaport Global Securities Weighs in on Aldeyra Therapeutics, Incs Q2 2018 Earnings (ALDX)Seaport Global Securities Weighs in on Aldeyra Therapeutics, Inc's Q2 2018 Earnings (ALDX)
www.americanbankingnews.com - May 18 at 8:14 AM
Aldeyra Therapeutics (ALDX) PT Set at $23.00 by Cantor FitzgeraldAldeyra Therapeutics (ALDX) PT Set at $23.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 16 at 3:41 PM
Aldeyra Therapeutics (ALDX) Releases  Earnings Results, Misses Estimates By $0.06 EPSAldeyra Therapeutics (ALDX) Releases Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 16 at 12:05 PM
Aldeyra Therapeutics (ALDX) Misses Q1 EPS by 4cAldeyra Therapeutics (ALDX) Misses Q1 EPS by 4c
www.streetinsider.com - May 15 at 4:42 PM
Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call TranscriptAldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 4:42 PM
Aldeyra Therapeutics Announces First Quarter 2018 Financial ResultsAldeyra Therapeutics Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 15 at 9:43 AM
Aldeyra Therapeutics, Inc (ALDX) Receives Average Recommendation of "Buy" from AnalystsAldeyra Therapeutics, Inc (ALDX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 1:30 AM
Aldeyra Therapeutics (ALDX) Set to Announce Quarterly Earnings on TuesdayAldeyra Therapeutics (ALDX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 12 at 8:15 PM
BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And StrategyBRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy
www.reuters.com - May 11 at 10:15 AM
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and StrategyAldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
finance.yahoo.com - May 10 at 9:28 AM
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial ResultsAldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:15 AM
Zacks: Analysts Expect Aldeyra Therapeutics, Inc (ALDX) Will Announce Earnings of -$0.37 Per ShareZacks: Analysts Expect Aldeyra Therapeutics, Inc (ALDX) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - May 4 at 6:14 PM
Aldeyra Therapeutics (ALDX) Highlights Dry Eye Disease Phase 2a Clinical Trial ResultsAldeyra Therapeutics (ALDX) Highlights Dry Eye Disease Phase 2a Clinical Trial Results
www.streetinsider.com - May 4 at 9:05 AM
Aldeyra Therapeutics (ALDX) Upgraded at ValuEngineAldeyra Therapeutics (ALDX) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 1:12 AM
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in ...Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in ...
www.prnewswire.com - May 1 at 9:08 AM
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual MeetingAldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
finance.yahoo.com - May 1 at 9:08 AM
Late-stage study underway for Aldeyras allergic conjunctivitis med reproxalap; shares up 2%Late-stage study underway for Aldeyra's allergic conjunctivitis med reproxalap; shares up 2%
seekingalpha.com - April 24 at 4:36 PM
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical TrialAldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
finance.yahoo.com - April 24 at 9:10 AM
Active-Investors: Free Post Earnings Research Report: Curis Quarterly Revenue Jumped 38.10%Active-Investors: Free Post Earnings Research Report: Curis' Quarterly Revenue Jumped 38.10%
www.finanznachrichten.de - April 19 at 9:32 AM
Aldeyra Therapeutics, Inc (ALDX) Given Consensus Recommendation of "Buy" by BrokeragesAldeyra Therapeutics, Inc (ALDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 1:18 AM
Aldeyra Therapeutics (ALDX) PT Set at $18.00 by HC WainwrightAldeyra Therapeutics (ALDX) PT Set at $18.00 by HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM
Neuron Systems (ALDX) Lowered to Strong Sell at ValuEngineNeuron Systems (ALDX) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 9 at 12:10 PM
Cowen Reaffirms "Hold" Rating for Aldeyra Therapeutics (ALDX)Cowen Reaffirms "Hold" Rating for Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - April 9 at 6:03 AM
Brokers Offer Predictions for Aldeyra Therapeutics Incs FY2018 Earnings (ALDX)Brokers Offer Predictions for Aldeyra Therapeutics Inc's FY2018 Earnings (ALDX)
www.americanbankingnews.com - April 6 at 6:58 AM
Aldeyra Therapeutics (ALDX) Rating Lowered to Sell at Zacks Investment ResearchAldeyra Therapeutics (ALDX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 4 at 4:43 PM
Aldeyra Therapeutics (ALDX) Releases  Earnings Results, Misses Estimates By $0.04 EPSAldeyra Therapeutics (ALDX) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 30 at 7:52 AM
Aldeyra Therapeutics (ALDX) Downgraded by Zacks Investment Research to HoldAldeyra Therapeutics (ALDX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 29 at 9:04 PM
Aldeyra Therapeutics reports FY 2017 resultsAldeyra Therapeutics reports FY 2017 results
seekingalpha.com - March 29 at 4:39 PM
Cantor Fitzgerald Analysts Give Aldeyra Therapeutics (ALDX) a $23.00 Price TargetCantor Fitzgerald Analysts Give Aldeyra Therapeutics (ALDX) a $23.00 Price Target
www.americanbankingnews.com - March 29 at 3:36 PM
Aldeyra Therapeutics, Inc. to Host Earnings CallAldeyra Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 29 at 9:33 AM
Aldeyra Therapeutics Announces Year End 2017 Financial ResultsAldeyra Therapeutics Announces Year End 2017 Financial Results
finance.yahoo.com - March 29 at 9:33 AM
Aldeyra Therapeutics (ALDX) Upgraded to "Hold" by ValuEngineAldeyra Therapeutics (ALDX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Aldeyra Therapeutics Inc (ALDX) Given Average Recommendation of "Buy" by BrokeragesAldeyra Therapeutics Inc (ALDX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 25 at 1:40 AM
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results - PR Newswire (press release)Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 22 at 4:52 PM
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial ResultsAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
finance.yahoo.com - March 22 at 4:52 PM
Aldeyra Therapeutics (ALDX) to Release Earnings on WednesdayAldeyra Therapeutics (ALDX) to Release Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:18 AM
Aldeyra Therapeutics Inc (ALDX) Expected to Announce Earnings of -$0.32 Per ShareAldeyra Therapeutics Inc (ALDX) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - March 14 at 1:06 PM
Canaccord Genuity Reiterates "Buy" Rating for Aldeyra Therapeutics (ALDX)Canaccord Genuity Reiterates "Buy" Rating for Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - March 13 at 9:08 PM
Seaport Global Securities Comments on Aldeyra Therapeutics Incs FY2017 Earnings (ALDX)Seaport Global Securities Comments on Aldeyra Therapeutics Inc's FY2017 Earnings (ALDX)
www.americanbankingnews.com - March 5 at 1:10 AM
Aldeyra Therapeutics (ALDX) & Vical (VICL) Head-To-Head ComparisonAldeyra Therapeutics (ALDX) & Vical (VICL) Head-To-Head Comparison
www.americanbankingnews.com - March 3 at 4:20 PM
Seaport Global Securities Reaffirms Buy Rating for Aldeyra Therapeutics (ALDX)Seaport Global Securities Reaffirms Buy Rating for Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - March 3 at 9:18 AM
Aldeyra Therapeutics (ALDX) Announces Pact with Janssen for Systemic Inflammatory DiseasesAldeyra Therapeutics (ALDX) Announces Pact with Janssen for Systemic Inflammatory Diseases
www.streetinsider.com - February 28 at 9:46 AM
Aldeyra Therapeutics Inc (ALDX) Receives Average Rating of "Buy" from AnalystsAldeyra Therapeutics Inc (ALDX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 28 at 1:26 AM
Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory DiseasesAldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
finance.yahoo.com - February 27 at 9:53 AM
Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingAldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
finance.yahoo.com - February 21 at 9:52 AM
Whats Next For Aldeyra Therapeutics? - Seeking AlphaWhat's Next For Aldeyra Therapeutics? - Seeking Alpha
seekingalpha.com - February 2 at 3:25 PM
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial - PR Newswire (press release)Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial - PR Newswire (press release)
www.prnewswire.com - February 1 at 3:24 PM
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical TrialAldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
finance.yahoo.com - January 30 at 3:23 PM

SEC Filings

Aldeyra Therapeutics (NASDAQ:ALDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aldeyra Therapeutics (NASDAQ:ALDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aldeyra Therapeutics (NASDAQ ALDX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.